Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-05-09
2010-06-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S654000, C564S367000
Reexamination Certificate
active
07728040
ABSTRACT:
Polyamine compounds, method of synthesis and method of use for anti-cancer purposes, for enhancing the activity of existing anti-cancer drugs, as well as, for inhibiting N-Methyl-D-Aspartate (NMDA) receptors found in neurotransmission systems are provided. Certain polyamine motifs have been identified that can be attached to toxic agents to facilitate their access to cancer cells as well as polyamine compounds of surprising cytotoxicity with selectivity in killing cancer cells, and surprising utility in the treatment of Alzheimer's disease and brain stroke. It includes an illustrative conjugate system with examples of a triamine or a tetraamine appended to a cytotoxic agent. Included is a general strategy to enhance cell uptake by attaching a polyamine vectoring system with an example of a triamine vector attached to an existing anti-cancer drug to improve its chemotherapeutic potency. There is an illustration of tetraamine derivatives which have surprising enhanced selectivity in inhibiting N-methyl-D-aspartate (NMDA) receptors involved in neurotransmission. Several ligands can affect the activity of this receptor, which has been shown to initiate cell death under stroke conditions (lack of oxygen). Tetraamine derivatives which bind or inhibit the action of the NMDA receptor provide new therapy for NMDA-associated human diseases, such as Alzheimer's disease and stroke.
REFERENCES:
patent: 5109024 (1992-04-01), Prakash et al.
patent: 5719193 (1998-02-01), Bowlin et al.
patent: 5866613 (1999-02-01), Bergeron et al.
patent: 6281371 (2001-08-01), Klosel et al.
patent: 6319956 (2001-11-01), Iwata
patent: 6342534 (2002-01-01), Bergeron
patent: 7208528 (2007-04-01), Vermeulin et al.
patent: 2002/0067472 (2002-06-01), Iwata
Bergeron, R., et al. “Impact of Polyamine Analogues on the NMDA Receptor” J. Med. Chem. (1995) vol. 38, pp. 425-428.
Wang, C., et al. “Molecular Requirements for Targeting the Polyamine Transport System” J. Med. Chem. (2003) vol. 46, pp. 2672-2682.
Wang, C. et al. “Synthesis and Biological Evaluation of N1- (Anthracen-9-ylmethyl) triamines as Molecular Recognition Elements for the Polyamine Transporter” J. Med. Chhem. (2003) vol. 46, pp. 2263-2671.
Wang, C., et al. “Anthraquinone Polyamines: Novel Channel Blockers to Study N-Mehtyl- D-Asparate Receptors” The Journal of Pharmacology and Experimental Therapeutics, (2004) vol. 309, pp. 884-893.
Gardner, R.A., et al. “N1-Substitute Effects i the Selective Delivery of Polyamine Conjugates into Cells Containing Active Polyamine Transporters” (2004) vol. 47, pp. 6055-6069.
Williams, K. et al. “Effects of Polyamines of the Binding of [3H]MK-801 to the N-Methyl-Daspartate Receptor: Pharmacological Evidence for the Existence of a Polyamine Recognition Site” Molecular Pharmacology, (1989) vol. 36, pp. 575-581.
Williams, K. et al. “Sensitivity of the Non-Methyl-D-Aspartate Receptor to Polyamines Controlled by NR2 Subunits” Molecular Pharmacology (1994) vol. 45, pp. 803-809.
Kantamneni Shobha
Law Offices of Brian S. Steinberger , P.A.
Morlin Joyce P.
Padmanabhan Sreeni
Steinberger Brian S.
LandOfFree
Polyamine conjugates as selective NMDA inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyamine conjugates as selective NMDA inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyamine conjugates as selective NMDA inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189138